Granules India announces three observations from USFDA at its US-based facility

31 Jan 2022 , 08:49 AM

The audit is a pre-approval inspection (PAI) for two of its product applications filed from this facility. The US-based drug regulatory body, USFDA issued three minor observations during the audit conducted at the facility.

Commenting on the audit, Priyanka Chigurupati, the executive director of GPI, stated, We are glad to have completed yet another audit with minor observations that we will respond to within the stipulated time period.

On a consolidated basis, Granules Indias net profit dropped 50.7% to Rs 80.68 crore on a 3.5% increase in net sales to Rs 888.33 crore in Q2 FY22 over Q2 FY21.

Hyderabad-based Granules India is a vertically integrated fast growing Indian pharmaceutical company. It is present in the manufacturing of entire value chain – from Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs) and Finished Dosages (FDs).

Shares of Granules India advanced 2.18% to close at Rs 300.50 on BSE yesterday, 31 January 2022.

Powered by Capital Market – Live News